Roger Ulrich, Ph.D.

Roger joined Frazier Healthcare Partners' Life Sciences team in 2016 as a Senior Advisor and has worked with Frazier-backed portfolio companies for over 15 years. He was with Acerta Pharma as both a member of the company’s founding Board of Directors and as Chief Scientific Officer through its majority-share acquisition by AstraZeneca for $7 billion. Acerta/AstraZeneca are developing acalabrutinib, a second-generation Bruton’s tyrosine kinase (BTK) inhibitor approved as Calquence for the treatment of patients with CLL/SLL or MCL. He was previously co-founder and Chief Development Officer with Calistoga Pharmaceuticals, a Frazier portfolio company acquired by Gilead Sciences, and Roger continued with Gilead to help complete the development of idelalisib, an isoform-selective PI3K inhibitor now marketed as Zydelig. Roger was also part of the founding team and served as Chief Scientific Officer for Phathom Pharmaceuticals (NASDAQ: PHAT). He served on the scientific advisory board of Mavupharma, a Frazier-founded company focused on novel approaches to selectively target the STING (stimulator of interferon genes) pathway, until its acquisition by AbbVie. He currently serves on the board of directors of Lengo Therapeutics, as well as the scientific advisory boards of Cirius Therapeutics and Inipharm.

Prior to Calistoga, Roger was Senior Scientific Director with Merck Research Laboratories, where he helped guide the Merck integration of Seattle-based Rosetta Inpharmatics. Prior to Merck, he was Director of Drug Safety Evaluation at Abbott Laboratories, and was Senior Scientist with both The Upjohn Company and Pharmacia & Upjohn Inc. Roger directly contributed to the discovery, development, approval, and life cycle of several products including Camptosar, Zyvox, Spexil, Colestid Tablets, Actos, Kaletra and Humira. Prior to his career in the pharmaceutical industry, he held research positions at West Virginia and Michigan State Universities, and at Argonne National Laboratories. He currently serves on the boards of Link Immunotherapeutics, Kartos Therapeutics and Aminex, and serves as a scientific advisor to several small companies.

Roger received his Ph.D. in Cellular and Molecular Biology from West Virginia University, where he studied the role of protein kinases and cytoskeletal function in cancer. He holds several patents, has authored more than 120 publications, and is a Fellow of the Academy of Toxicological Sciences.